Showing 4821-4830 of 5623 results for "".
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- UK to Test Weekly, Swabless COVID-19 Screening for Health Care Workers, Students and Morehttps://modernod.com/news/uk-to-test-weekly-swabless-covid-19-screening-for-health-care-workers-students-and-more/2477918/The UK government will begin testing a new, swabless coronavirus test, designed to be completed at home on a weekly basis by spitting into a collection tube, according to a FierceBiotech
- Viela Bio Announces FDA Approval of Uplinza (Inebilizumab) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/viela-bio-announces-fda-approval-of-uplinza-inebilizumab-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd/2477912/Viela Bio announced the FDA approval of Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is the first and only B cell-depleting antibody approved for the disease. Uplizna is indicated for those who are
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),
- Fitbit Joins Growing List of Companies Offering Back-to-Work Health Screening Toolshttps://modernod.com/news/fitbit-joins-growing-list-of-companies-offering-back-to-work-health-screening-tools/2477908/Device maker Fitbit is the latest technology company to jump into the back-to-work business, according to a FierceHealthcare
- Study Examines Firework-Related Ocular Injuries in the UShttps://modernod.com/news/study-examines-firework-related-ocular-injuries-in-the-us/2477904/Every year,
- NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical for Ophthalmic Quinolone Antibiotichttps://modernod.com/news/ntc-grants-license-and-distribution-rights-in-israel-to-taro-pharmaceutical-for-ophthalmic-quinolone-antibiotic/2477905/NTC has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries. The product combines a quinolone antibiotic with an anti-inflammatory steroid
- NYU Langone Names New Chair of Ophthalmologyhttps://modernod.com/news/nyu-langone-names-new-chair-of-ophthalmology/2477903/Kathryn A. Colby, MD, PhD, an internationally renowned physician–scientist, has been appointed chair of the Department of Ophthalmology at NYU Langone Health. She assumes her new post this fall. Dr. Colby is currently the Louis Block Professor and chair of the Department of Ophthalmology a
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise
- FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquinehttps://modernod.com/news/fda-revokes-emergency-use-authorization-for-chloroquine-and-hydroxychloroquine/2477896/The FDA revoked the emergency use authorization (EUA) that allowed for chloroquine and hydroxychloroquine to be used to treat certain hospitalized patients with COVID-19, according to an FDA news release. The agency determined that th